Zacks Research Analysts Decrease Earnings Estimates for AXSM

Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) - Zacks Research reduced their Q1 2027 earnings per share (EPS) estimates for Axsome Therapeutics in a research note issued on Monday, April 7th. Zacks Research analyst R. Department now forecasts that the company will post earnings of $0.75 per share for the quarter, down from their prior estimate of $0.92. The consensus estimate for Axsome Therapeutics' current full-year earnings is ($2.79) per share. Zacks Research also issued estimates for Axsome Therapeutics' FY2027 earnings at $5.37 EPS.

AXSM has been the topic of several other reports. Jefferies Financial Group began coverage on shares of Axsome Therapeutics in a research note on Monday, April 7th. They set a "buy" rating and a $200.00 price target on the stock. Truist Financial boosted their target price on Axsome Therapeutics from $190.00 to $200.00 and gave the company a "buy" rating in a report on Wednesday, February 19th. William Blair restated an "outperform" rating on shares of Axsome Therapeutics in a research note on Tuesday, February 18th. Deutsche Bank Aktiengesellschaft assumed coverage on Axsome Therapeutics in a research note on Tuesday, February 11th. They issued a "buy" rating and a $176.00 price objective for the company. Finally, Royal Bank of Canada raised their target price on shares of Axsome Therapeutics from $143.00 to $192.00 and gave the stock an "outperform" rating in a research report on Wednesday, February 19th. One equities research analyst has rated the stock with a hold rating and sixteen have issued a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $169.80.

Remove Ads

Axsome Therapeutics Stock Up 2.5 %

NASDAQ:AXSM traded up $2.41 during trading hours on Tuesday, hitting $98.06. The company's stock had a trading volume of 867,734 shares, compared to its average volume of 679,227. The stock has a market capitalization of $4.78 billion, a P/E ratio of -16.37 and a beta of 0.88. The company has a current ratio of 2.11, a quick ratio of 2.04 and a debt-to-equity ratio of 3.22. The stock has a fifty day moving average of $119.51 and a 200-day moving average of $102.07. Axsome Therapeutics has a 52-week low of $64.11 and a 52-week high of $139.13.

Axsome Therapeutics (NASDAQ:AXSM - Get Free Report) last announced its quarterly earnings data on Tuesday, February 18th. The company reported ($0.96) EPS for the quarter, beating analysts' consensus estimates of ($0.97) by $0.01. The company had revenue of $118.77 million for the quarter, compared to the consensus estimate of $117.83 million. Axsome Therapeutics had a negative net margin of 74.47% and a negative return on equity of 223.51%.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in AXSM. NBC Securities Inc. bought a new stake in shares of Axsome Therapeutics in the 1st quarter valued at approximately $31,000. Raiffeisen Bank International AG bought a new stake in Axsome Therapeutics in the fourth quarter worth approximately $51,000. Assetmark Inc. acquired a new position in shares of Axsome Therapeutics during the 4th quarter worth $52,000. R Squared Ltd bought a new position in shares of Axsome Therapeutics during the 4th quarter valued at $64,000. Finally, Aquatic Capital Management LLC acquired a new stake in shares of Axsome Therapeutics in the 4th quarter valued at $76,000. 81.49% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, CFO Nick Pizzie sold 3,000 shares of the firm's stock in a transaction that occurred on Friday, February 14th. The shares were sold at an average price of $131.07, for a total value of $393,210.00. Following the completion of the transaction, the chief financial officer now owns 42,187 shares of the company's stock, valued at approximately $5,529,450.09. This trade represents a 6.64 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 22.40% of the company's stock.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.